drugset / Trial / NCT01486017

A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K

NCT01486017

Phase 1 Completed 30 enrolled Astellas Pharma Inc
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to determine the relative bioavailability and pharmacokinetic profiles from three strengths of a new tablet formulation of ASP015K and to evaluate the safety and tolerability after a single dose of three different strengths of a new tablet formulation.

Timeline

Start
2011-09
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject peficitinib Small molecule Oral

Indications

No indication recorded.